Eisai Co., Ltd.

This early-phase study tests a new drug called E7090, alone or with other cancer medicines, in people with a common type of advanced breast cancer (ER+, HER2-). The main goal is to find safe doses and understand side effects. About 51 adults whose cancer has returned or spread wi…

This study tests a new combination of two drugs (E7389 liposomal and nivolumab) in people with advanced solid tumors that haven't responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 125 participants with specif…

This early-phase study tests a new liposomal formulation of the drug E7389 in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and evaluate side effects. The study includes patients with breast cancer, aden…

This study looks at the safety of the drug tazemetostat in people with a type of lymphoma (follicular lymphoma) that has come back or not responded to treatment and has a specific gene change (EZH2 mutation). About 145 participants in Japan will be observed during routine care to…

This early-stage study tests a new drug called E7386 in people with advanced solid tumors, including colorectal cancer, who have no other treatment options. The main goal is to check the drug's safety and find the right dose. About 70 participants will take part, and the study is…